Co-Diagnostics Inc (CODX)

$0.33 -0.04 (-11.83%)
Market Cap 24.13M
Revenue (ttm) 3.92M
Net Income (ttm) -37.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -960.20%
Debt to Equity Ratio 0.00
Volume 1,883,356
Avg Vol 30,894,832
Day's Range N/A - N/A
Shares Out 60.89M
Stochastic %K 12%
Beta 0.98
Analysts Sell
Price Target $3.00

Company Profile

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus...

Industry: Medical Devices
Sector: Healthcare
Phone: 801 438 1036
Website: co-dx.com
Address:
2401 S. Foothill Dr., Suite D, Salt Lake City, United States
TheLittleMermaid
TheLittleMermaid Nov. 14 at 8:14 PM
$CODX 100% sure r/p will happen soon. Get out before it is too late.
0 · Reply
Stocksprofessional
Stocksprofessional Nov. 14 at 8:02 PM
$CODX
0 · Reply
DubLad76
DubLad76 Nov. 14 at 7:41 PM
$CODX This reminds me of a game I play with my kids. You’ll all know it. Who is going to blink first? With such large institutional investors, I can’t imagine that they will be particularly happy with the situation and will demand action so as their investments don’t go up in smoke. The likes of Vanguard don’t normally get these type of things wrong! So, Sit tight, ride it out.
1 · Reply
coolmate25
coolmate25 Nov. 14 at 7:24 PM
$CODX Fck Humanity ! Coward Mfs can't even hold stock , they think they will fight alien invasion lol 😂.
0 · Reply
ryan824725
ryan824725 Nov. 14 at 7:22 PM
$CODX hangin on but fck man guess ill avg down if we end up under .20
0 · Reply
ryan824725
ryan824725 Nov. 14 at 7:07 PM
$CODX how tf did this pump to $1.30 late October and tank to this .. comedic
1 · Reply
Antiquarian
Antiquarian Nov. 14 at 6:20 PM
$CODX
0 · Reply
Minutiae
Minutiae Nov. 14 at 5:22 PM
$CODX A Reverse Stock Split or an OTC Listing 😟❓ Co-Dx has recently raised funds by offering CODX shares at $0.55 and $0.40 per share. Institutional holders bought up these shares with no problem. Therefore, institutional holders of CODX shares are not locked into only accepting Nasdaq listed stocks. So long as Co-Dx has great potential in its products succeeding in the Molecular Diagnostic Test market and remains capable of raising revenue, Co-Dx should be able to continue to function as an OTC listed stock. A reverse stock split is extremely undesirable to CODX shareholders. Therefore, voting against a reverse stock split is the logical action to take. Google AI Question Do institutional holders mandate a Nasdaq listing to invest in a stock?
1 · Reply
ryan824725
ryan824725 Nov. 14 at 5:15 PM
$CODX what kind of averages are we all holding here? Im .47 not thrilled
1 · Reply
bundy3333
bundy3333 Nov. 14 at 4:51 PM
$CODX @Millones Everyone investing at least in stocks directly should understand SEC filings. It seems that since the Trump era, it's the opposite: just buy everything without even knowing what SEC is about, it will become part of MAGA. Have a nice ICE these days and don't care about ERA. 100.000 USD product revenue means less than 50 bucks per employee per day product sales ..... whereas Cash burn rate is more than 75.000 per day .... Still owning 600 shares as a reminder for myself to not believing CEOs, in case they are not afraid to o story telling since 2022 The next MULN like series of RS might be coming instead of putting the shares where they belong: to the OTC/PINK or just to Canada stock exchange by 2025/12/05
0 · Reply
Latest News on CODX
Co-Diagnostics, Inc. (CODX) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:01 PM EST - 20 hours ago

Co-Diagnostics, Inc. (CODX) Q3 2025 Earnings Call Transcript

Co-Diagnostics Reports Third Quarter 2025 Financial Results

Nov 13, 2025, 4:01 PM EST - 23 hours ago

Co-Diagnostics Reports Third Quarter 2025 Financial Results

Co-Diagnostics, Inc. (CODX) Discusses Saudi Arabia Joint Venture, AI Initiatives and Diagnostics Technology Developments Transcript

Nov 5, 2025, 10:51 PM EST - 8 days ago

Co-Diagnostics, Inc. (CODX) Discusses Saudi Arabia Joint Venture, AI Initiatives and Diagnostics Technology Developments Transcript

Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd

Nov 5, 2025, 9:00 AM EST - 9 days ago

Co-Diagnostics Engages Maxim Group to Pursue SPAC Transaction for its Indian Joint Venture, CoSara Diagnostics Pvt. Ltd

Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform

Nov 3, 2025, 9:00 AM EST - 11 days ago

Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform

Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast

Oct 31, 2025, 9:00 AM EDT - 14 days ago

Co-Diagnostics, Inc. Announces Third Quarter 2025 Earnings Release Date and Webcast

Co-Diagnostics to Host Fireside Chat on November 5th with CEO, Dwight Egan, to Discuss Recently Announced Definitive Agreement in Saudi Arabia

Oct 30, 2025, 1:57 PM EDT - 15 days ago

Co-Diagnostics to Host Fireside Chat on November 5th with CEO, Dwight Egan, to Discuss Recently Announced Definitive Agreement in Saudi Arabia

Co-Diagnostics, Inc. Announces Closing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 29, 2025, 12:51 PM EDT - 16 days ago

Co-Diagnostics, Inc. Announces Closing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 28, 2025, 9:33 AM EDT - 17 days ago

Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Co-Diagnostics Executive Leadership Team to Attend Global Health Exhibition 2025 in Riyadh, Saudi Arabia

Oct 22, 2025, 8:30 AM EDT - 23 days ago

Co-Diagnostics Executive Leadership Team to Attend Global Health Exhibition 2025 in Riyadh, Saudi Arabia

Co-Diagnostics Announces Development of Proprietary Sample Prep Instrument for PoC Testing

Oct 16, 2025, 9:30 AM EDT - 4 weeks ago

Co-Diagnostics Announces Development of Proprietary Sample Prep Instrument for PoC Testing

Co-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit

Oct 13, 2025, 9:30 AM EDT - 4 weeks ago

Co-Diagnostics, Inc. to Attend 2025 Maxim Growth Summit

Co-Diagnostics, Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30

Sep 30, 2025, 9:30 AM EDT - 6 weeks ago

Co-Diagnostics, Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30

Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Sep 18, 2025, 5:05 PM EDT - 2 months ago

Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Sep 17, 2025, 9:47 AM EDT - 2 months ago

Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains

Sep 11, 2025, 9:30 AM EDT - 2 months ago

Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers® to Confirm Reactivity Against Known Virus Strains

Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit

Sep 9, 2025, 9:30 AM EDT - 2 months ago

Co-Diagnostics, Inc. Honored at Utah Business 2025 Innovation Awards Summit

Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.

Aug 18, 2025, 9:30 AM EDT - 3 months ago

Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.

Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call Transcript

Aug 14, 2025, 7:42 PM EDT - 3 months ago

Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call Transcript

Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:01 PM EDT - 3 months ago

Co-Diagnostics, Inc. Reports Second Quarter 2025 Financial Results

Co-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast

Jul 31, 2025, 9:30 AM EDT - 3 months ago

Co-Diagnostics, Inc. Announces Second Quarter 2025 Earnings Release Date and Webcast

Co-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025

Jul 15, 2025, 9:30 AM EDT - 4 months ago

Co-Diagnostics, Inc. to Host Booth at WHX Kuala Lumpur on July 16-18, 2025

Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference

May 14, 2025, 9:30 AM EDT - 6 months ago

Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference

Co-Diagnostics, Inc. (CODX) Q1 2025 Earnings Call Transcript

May 8, 2025, 9:59 PM EDT - 6 months ago

Co-Diagnostics, Inc. (CODX) Q1 2025 Earnings Call Transcript

Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results

May 8, 2025, 4:01 PM EDT - 6 months ago

Co-Diagnostics, Inc. Reports First Quarter 2025 Financial Results

Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

Apr 29, 2025, 7:30 AM EDT - 7 months ago

Co-Diagnostics, Inc. Announces First Quarter 2025 Earnings Release Date and Webcast

Co-Diagnostics, Inc. (CODX) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 6:44 PM EDT - 8 months ago

Co-Diagnostics, Inc. (CODX) Q4 2024 Earnings Call Transcript

Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results

Mar 27, 2025, 4:01 PM EDT - 8 months ago

Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results

Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast

Mar 13, 2025, 9:30 AM EDT - 8 months ago

Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast

Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025

Mar 3, 2025, 9:30 AM EST - 9 months ago

Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025

Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version

Feb 24, 2025, 8:18 AM EST - 9 months ago

Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version

Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance

Feb 21, 2025, 4:00 PM EST - 9 months ago

Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance

Co-Diagnostics, Inc. to Participate at the Nasdaq Live from MarketSite Broadcast at Silicon Slopes 2025

Jan 7, 2025, 9:30 AM EST - 11 months ago

Co-Diagnostics, Inc. to Participate at the Nasdaq Live from MarketSite Broadcast at Silicon Slopes 2025

Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

Dec 10, 2024, 9:30 AM EST - 1 year ago

Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:49 PM EST - 1 year ago

Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript

Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 4:01 PM EST - 1 year ago

Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results

Co-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024

Nov 5, 2024, 9:30 AM EST - 1 year ago

Co-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024

Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast

Oct 25, 2024, 4:01 PM EDT - 1 year ago

Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast

Co-Diagnostics, Inc. to Host Booth at Medlab Africa in Cape Town on Oct 22-24, 2024

Oct 21, 2024, 9:30 AM EDT - 1 year ago

Co-Diagnostics, Inc. to Host Booth at Medlab Africa in Cape Town on Oct 22-24, 2024

Co-Diagnostics, Inc. to Host Booth at the 2024 UHCA/UCAL Fall Convention & Expo on Oct 2-3

Oct 2, 2024, 9:30 AM EDT - 1 year ago

Co-Diagnostics, Inc. to Host Booth at the 2024 UHCA/UCAL Fall Convention & Expo on Oct 2-3

Co-Diagnostics, Inc. to Accompany Utah Governor and WTC Utah on Trade Mission to South Korea and Japan

Sep 24, 2024, 9:30 AM EDT - 1 year ago

Co-Diagnostics, Inc. to Accompany Utah Governor and WTC Utah on Trade Mission to South Korea and Japan

Co-Diagnostics, Inc. Completes Updated Clade Ib Analysis of 2-Gene Mpox RUO Test

Sep 5, 2024, 9:30 AM EDT - 1 year ago

Co-Diagnostics, Inc. Completes Updated Clade Ib Analysis of 2-Gene Mpox RUO Test

Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C.

Aug 15, 2024, 9:30 AM EDT - 1 year ago

Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C.

Co-Diagnostics, Inc. (CODX) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 11:14 AM EDT - 1 year ago

Co-Diagnostics, Inc. (CODX) Q2 2024 Earnings Call Transcript

Co-Diagnostics, Inc. Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Co-Diagnostics, Inc. Reports Second Quarter 2024 Financial Results

Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago

Jul 29, 2024, 9:30 AM EDT - 1 year ago

Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago

Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast

Jul 25, 2024, 9:30 AM EDT - 1 year ago

Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast

Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States

Jul 2, 2024, 9:30 AM EDT - 1 year ago

Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States

Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21

Jun 18, 2024, 1:30 PM EDT - 1 year ago

Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

Jun 14, 2024, 9:30 AM EDT - 1 year ago

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

TheLittleMermaid
TheLittleMermaid Nov. 14 at 8:14 PM
$CODX 100% sure r/p will happen soon. Get out before it is too late.
0 · Reply
Stocksprofessional
Stocksprofessional Nov. 14 at 8:02 PM
$CODX
0 · Reply
DubLad76
DubLad76 Nov. 14 at 7:41 PM
$CODX This reminds me of a game I play with my kids. You’ll all know it. Who is going to blink first? With such large institutional investors, I can’t imagine that they will be particularly happy with the situation and will demand action so as their investments don’t go up in smoke. The likes of Vanguard don’t normally get these type of things wrong! So, Sit tight, ride it out.
1 · Reply
coolmate25
coolmate25 Nov. 14 at 7:24 PM
$CODX Fck Humanity ! Coward Mfs can't even hold stock , they think they will fight alien invasion lol 😂.
0 · Reply
ryan824725
ryan824725 Nov. 14 at 7:22 PM
$CODX hangin on but fck man guess ill avg down if we end up under .20
0 · Reply
ryan824725
ryan824725 Nov. 14 at 7:07 PM
$CODX how tf did this pump to $1.30 late October and tank to this .. comedic
1 · Reply
Antiquarian
Antiquarian Nov. 14 at 6:20 PM
$CODX
0 · Reply
Minutiae
Minutiae Nov. 14 at 5:22 PM
$CODX A Reverse Stock Split or an OTC Listing 😟❓ Co-Dx has recently raised funds by offering CODX shares at $0.55 and $0.40 per share. Institutional holders bought up these shares with no problem. Therefore, institutional holders of CODX shares are not locked into only accepting Nasdaq listed stocks. So long as Co-Dx has great potential in its products succeeding in the Molecular Diagnostic Test market and remains capable of raising revenue, Co-Dx should be able to continue to function as an OTC listed stock. A reverse stock split is extremely undesirable to CODX shareholders. Therefore, voting against a reverse stock split is the logical action to take. Google AI Question Do institutional holders mandate a Nasdaq listing to invest in a stock?
1 · Reply
ryan824725
ryan824725 Nov. 14 at 5:15 PM
$CODX what kind of averages are we all holding here? Im .47 not thrilled
1 · Reply
bundy3333
bundy3333 Nov. 14 at 4:51 PM
$CODX @Millones Everyone investing at least in stocks directly should understand SEC filings. It seems that since the Trump era, it's the opposite: just buy everything without even knowing what SEC is about, it will become part of MAGA. Have a nice ICE these days and don't care about ERA. 100.000 USD product revenue means less than 50 bucks per employee per day product sales ..... whereas Cash burn rate is more than 75.000 per day .... Still owning 600 shares as a reminder for myself to not believing CEOs, in case they are not afraid to o story telling since 2022 The next MULN like series of RS might be coming instead of putting the shares where they belong: to the OTC/PINK or just to Canada stock exchange by 2025/12/05
0 · Reply
ryan824725
ryan824725 Nov. 14 at 4:33 PM
$CODX climbing back
0 · Reply
Taylor1278
Taylor1278 Nov. 14 at 4:33 PM
$CODX talk about holding it DOWN!
0 · Reply
Stocksprofessional
Stocksprofessional Nov. 14 at 4:21 PM
$CODX from the earnings call: “We’re discussing different internal structures and exploring what this might look like, but we don’t have anything concrete or finalized to share with the market yet.” This kind of language usually hints at bigger strategic moves forming behind closed doors. When management openly mentions that they’re discussing different internal structures, it’s rarely random — it suggests serious planning and potential upgrades to the company’s operations. They may not be ready to reveal the details yet, but the fact that these conversations are happening at the leadership level signals that something significant is brewing, and once it’s finalized, it could position the company for stronger growth and better market confidence.
1 · Reply
DubLad76
DubLad76 Nov. 14 at 3:43 PM
$CODX still over 20% shorting this. It’s only a matter of time before the unwind. As frustrating as this stock is…. Hold on in there people!
0 · Reply
Millones
Millones Nov. 14 at 3:27 PM
$CODX Second Quarter 2024 “we continue to expect clinical evaluations to commence during the upcoming North American flu season” Dwight Egan https://www.investing.com/news/stock-market-news/earnings-call-codiagnostics-q2-earnings-reflect-growth-and-optimism-93CH-3566933
1 · Reply
ryan824725
ryan824725 Nov. 14 at 3:15 PM
$CODX yeaaah not lookin good here unfortunately
0 · Reply
Black_Jobs
Black_Jobs Nov. 14 at 2:43 PM
$CODX This seems like a shake. Everything is too purposeful. it seems as if they want to stock to drop & weak hands to exit before the next run. Send it to a nickle. I have fresh cash waiting for the bottom so I can double up $10,000 every five cent.
2 · Reply
Dany_italy
Dany_italy Nov. 14 at 2:21 PM
$CODX Who knows if it will recover from here or sink. From Italy, I have no possibility of voting or participating in class actions with NASDAQ. I would have to involve a lawyer, but I don't want to. I will try to be smart and reduce the average purchase price. In January, I will be on a mission to recover every last cent, a kind of revenge. In any case, I will do it
3 · Reply
Mallorcafiles
Mallorcafiles Nov. 14 at 2:05 PM
$CODX Hope, the shutdown will end.
1 · Reply
markn1689
markn1689 Nov. 14 at 2:05 PM
$CODX I definitely am starting to feel the tension 👍. It’s gonna get good soon. this technology and research isn’t gonna just go away
1 · Reply
Millones
Millones Nov. 14 at 2:03 PM
$CODX The Company is a defendant in one class action claim and three derivative actions claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company is also a party to three civil actions, two in the US and the other in the United Kingdom. Each of the civil actions is based on breach of contract claims against the Company.
0 · Reply
leosp11
leosp11 Nov. 14 at 1:33 PM
$CODX Time bail for me.
1 · Reply